23.93
1.77%
-0.43
시간 외 거래:
23.94
0.01
+0.04%
전일 마감가:
$24.36
열려 있는:
$21.62
하루 거래량:
2.29M
Relative Volume:
2.75
시가총액:
$1.97B
수익:
$352.57M
순이익/손실:
$-143.01M
주가수익비율:
-5.306
EPS:
-4.51
순현금흐름:
$-153.40M
1주 성능:
+7.94%
1개월 성능:
+2.22%
6개월 성능:
+3.46%
1년 성능:
-2.29%
빔 테라퓨틱스 Stock (BEAM) Company Profile
명칭
Beam Therapeutics Inc
전화
857-327-8775
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
빔 테라퓨틱스 Stock (BEAM) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-01-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
2023-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
2023-12-08 | 다운그레이드 | Jefferies | Buy → Hold |
2023-10-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
2023-10-20 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
2023-03-21 | 개시 | Bernstein | Mkt Perform |
2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
2022-12-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
2022-12-13 | 개시 | Citigroup | Buy |
2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
2022-04-28 | 개시 | Credit Suisse | Neutral |
2022-01-05 | 개시 | Guggenheim | Buy |
2021-10-19 | 개시 | SVB Leerink | Outperform |
2021-09-24 | 재개 | Stifel | Buy |
2021-09-10 | 개시 | BofA Securities | Buy |
2021-05-11 | 개시 | Redburn | Buy |
2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
2021-02-16 | 개시 | Wells Fargo | Overweight |
2021-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2021-01-06 | 개시 | Stifel | Hold |
2020-08-05 | 개시 | William Blair | Outperform |
2020-03-02 | 개시 | Barclays | Overweight |
2020-03-02 | 개시 | JP Morgan | Overweight |
2020-03-02 | 개시 | Jefferies | Buy |
2020-03-02 | 개시 | Wedbush | Outperform |
모두보기
빔 테라퓨틱스 주식(BEAM)의 최신 뉴스
Beam Is Laser-Focused On ASH As It Reports Promising Sickle Cell Data, And A Death - Scrip
SCD phase I/II death shines Beam on ‘very real’ busulfan risk - BioWorld Online
Beam’s Base-Editing Sickle Cell Therapy Shows Early Promise, But a Fatality Overshadows Results - MedCity News
Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial - Yahoo Finance
JPMorgan maintains $48 target on Beam Therapeutics stock - Investing.com
Stifel maintains $69 target on Beam Therapeutics stock - Investing.com
Beam Therapeutics' early base editing clinical data overshadowed by patient death - The Business Journals
Beam Therapeutics (NASDAQ:BEAM) Shares Gap Down Following Weak Earnings - MarketBeat
Beam Therapeutics sustains Outperform stock rating on clinical data - Investing.com
Beam Therapeutics (NASDAQ:BEAM) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
Beam Therapeutics sustains Outperform stock rating on clinical data By Investing.com - Investing.com UK
Beam stock falls after fatality in gene editing trial - Seeking Alpha
Sickle cell patient dies in Beam study of base editing therapy - BioPharma Dive
Beam Therapeutics to Present Data Across Hematology - GlobeNewswire
Beam Therapeutics' Sickle Cell Treatment Shows Promising Results in First Clinical Trial | BEAM Stock News - StockTitan
Beam Therapeutics Inc Reports Q3 2024 EPS of $1.17, Revenue of $14.27 Million, Slightly Missing Estimates - GuruFocus.com
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Beam Therapeutics Q3 24 Earnings Conference Call At 8:30 AM ET - Nasdaq
Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs - GlobeNewswire
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Shares Up 6.5%Still a Buy? - MarketBeat
Beam Therapeutics (BEAM) Stock Surges with Strong Trading Volume - GuruFocus.com
Beam Therapeutics's Earnings: A Preview - Benzinga
Beam Therapeutics (BEAM) Stock Surges Amid Market Activity - GuruFocus.com
Beam Therapeutics (BEAM): Promising Gene Editing Stock with Base Editing Technology - Insider Monkey
(BEAM) Investment Analysis - Stock Traders Daily
Beam Therapeutics (BEAM) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds - Insider Monkey
64,313 Shares in Beam Therapeutics Inc. (NASDAQ:BEAM) Bought by International Assets Investment Management LLC - MarketBeat
Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting - ForexTV.com
Beam Therapeutics to Hold Conference Call to Discuss Third - GlobeNewswire
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences - GlobeNewswire
We're Interested To See How Beam Therapeutics (NASDAQ:BEAM) Uses Its Cash Hoard To Grow - Yahoo Finance
Insufficient Growth At Beam Therapeutics Inc. (NASDAQ:BEAM) Hampers Share Price - Simply Wall St
Beam Therapeutics' SWOT analysis: base editing biotech stock faces pivotal year By Investing.com - Investing.com South Africa
Beam Therapeutics' SWOT analysis: base editing biotech stock faces pivotal year - Investing.com
Beam Therapeutics (BEAM): A Small-Cap Leader in Precision Genetic Medicine - Yahoo Finance
8 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
(BEAM) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Beam Therapeutics (BEAM): The Next Frontier in Biotech - TipRanks
State Street Corp's Strategic Acquisition in Beam Therapeutics Inc - Yahoo Finance
Beam Therapeutics (NASDAQ:BEAM) Trading Down 6.6% After Insider Selling - MarketBeat
Scotiabank Initiates Coverage of Beam Therapeutics (BEAM) with Sector Perform Recommendation - Nasdaq
Beam Therapeutics president sells $1.34 million in stock - Investing.com
Beam Therapeutics president sells $1.34 million in stock By Investing.com - Investing.com South Africa
Insider Selling: Beam Therapeutics Inc. (NASDAQ:BEAM) President Sells 51,110 Shares of Stock - MarketBeat
BEAM Crosses Above Key Moving Average Level - Nasdaq
Examining Beam Therapeutics Inc (BEAM) more closely is necessary - US Post News
Beam Therapeutics (NASDAQ:BEAM) Earns Sector Outperform Rating from Analysts at Scotiabank - MarketBeat
Beam Therapeutics Inc [BEAM] Investment Guide: What You Need to Know - Knox Daily
What is Beam Therapeutics Inc (BEAM) Stock Return on Shareholders’ Capital? - SETE News
빔 테라퓨틱스 (BEAM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
빔 테라퓨틱스 주식 (BEAM) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Ciaramella Giuseppe | President |
Oct 14 '24 |
Sale |
26.27 |
51,110 |
1,342,752 |
160,260 |
자본화:
|
볼륨(24시간):